Recently, the Suzhou city announced the list of 2023 “Unicorn” Cultivation Enterprises and Biomissile Pharmaceuticals Co., Ltd. was honored to be selected. 

About Suzhou City’s “Unicorn” Cultivation Enterprises

As an important bellwether of the new economy development, Suzhou “Unicorn” Enterprises refers to the strong vitality of scientific and technological innovation, representing the development trend of emerging industries, and is valued at least $100M USD with less than five years of establishment. The honored enterprise is in the strategic emerging industry of Suzhou city with business management sustainability, strong disruptive innovation capability, remarkable innovation achievement and explosive growth possibility.

About Biomissile

Biomissile Pharmaceuticals Co., Ltd. is a clinical stage biotech company focusing on developing fully human domain antibody (UDAB^TM) and multi-specific antibody (UDAB-M^TM) to fight a range of diseases with global unmet medical needs. We aim to become a premium innovative biopharmaceutical company based on our unique platform technologies, strong pipeline, and outstanding team. We have established five proprietary platforms for rapid antibody discovery and optimization, including the leading platforms for fully human domain antibody (UDAB^TM) and multi-specific antibody (UDAB-M^TM), as well as the largest libraries of phage, yeast and mammalian cell display platforms. Relying on the strong platform technologies, the company has more than 10 innovative candidates under development in a short period of time, including several First-in-Class domain antibodies (VH) and multi-specific UDAB-M^TM molecules to specifically activate immune cells in the tumor microenvironment (TME). So far, two leading projects are in clinical stages (in Phase I & II) and the third one is in IND filing stage. 

Biomissile has successfully assembled a global, seasoned leadership team in antibody discovery, manufacturing, clinical, registration and business development. The core team members are composed of experts with an average of more than 20 years’ experience in biological R&D and commercialization. The company has a state-of-the-art R&D lab in Shanghai, a future GMP facility in Suzhou, and a global regulatory & BD team in Boston, USA. We are committed to the disruptive innovation of biological drugs to benefit patients worldwide.

Link to the news in Chinese:
https://mp.weixin.qq.com/s/YDHraU3wR_iJwoQ5569fKA

BD: bd@biomissile.com
HR: hr@biomissile.com
Website: www.biomissile.com